Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$25.15 -1.2%	$22.59	$13.40 ▼ $25.88	$4.29B	0.7	1.74 million shs	1.52 million shs
IMVT Immunovant	$15.89 +4.5%	$16.54	$12.72 ▼ $34.47	$2.65B	0.66	1.27 million shs	1.05 million shs
KALV KalVista Pharmaceuticals	$12.59 +2.8%	$13.51	$7.30 ▼ $16.32	$611.93M	0.05	933,021 shs	753,352 shs
MTSR Metsera	$30.87 0.0%	$33.21	$12.30 ▼ $47.40	$3.24B	N/A	1.40 million shs	1.11 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+2.54%	+7.66%	+21.31%	+48.31%	+66.45%
IMVT Immunovant	+3.05%	-7.87%	-16.11%	+10.38%	-48.68%
KALV KalVista Pharmaceuticals	-2.08%	-6.13%	-15.63%	+8.02%	-5.55%
MTSR Metsera	+2.46%	-7.41%	-21.38%	+26.09%	+3,087,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9829 of 5 stars	3.3	3.0	0.0	0.0	2.1	4.2	2.5
IMVT Immunovant	2.2659 of 5 stars	4.4	0.0	0.0	0.0	2.4	1.7	0.0
KALV KalVista Pharmaceuticals	3.8873 of 5 stars	3.6	1.0	0.0	4.4	2.1	1.7	0.6
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	14.79% Upside
IMVT Immunovant	2.83	Moderate Buy	$35.20	121.52% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	108.78% Upside
MTSR Metsera	3.00	Buy	$55.00	78.17% Upside

Current Analyst Ratings Breakdown

Latest KALV, IMVT, ACAD, and MTSR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.43	$0.70 per share	36.11	$4.87 per share	5.17
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	$4.28 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	18.91	33.10	6.48	21.80%	14.69%	9.41%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	N/A
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest KALV, IMVT, ACAD, and MTSR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
7/28/2025	Q2 2025	MTSR Metsera	N/A	-$0.66	N/A	-$0.66	N/A	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
IMVT Immunovant	N/A	12.32	11.16
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
MTSR Metsera	N/A	5.26	5.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
IMVT Immunovant	47.08%
KALV KalVista Pharmaceuticals	N/A
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
IMVT Immunovant	1.80%
KALV KalVista Pharmaceuticals	10.50%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
IMVT Immunovant	120	174.32 million	167.99 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

KALV, IMVT, ACAD, and MTSR Headlines

Recent News About These Companies

Metsera (NASDAQ:MTSR) Stock Price Down 4.5% - What's Next?

August 5, 2025 | marketbeat.com

76,824 Shares in Metsera Inc. (NASDAQ:MTSR) Acquired by TD Asset Management Inc

August 3, 2025 | marketbeat.com

Bank of New York Mellon Corp Takes $884,000 Position in Metsera Inc. (NASDAQ:MTSR)

August 3, 2025 | marketbeat.com

Brokers Set Expectations for Metsera FY2025 Earnings

August 1, 2025 | marketbeat.com

We're Hopeful That Metsera (NASDAQ:MTSR) Will Use Its Cash Wisely

July 31, 2025 | finance.yahoo.com

Metsera (NASDAQ:MTSR) Stock Price Down 9.7% - Here's What Happened

July 30, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Posts Earnings Results

July 29, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Gap Down - Here's Why

July 29, 2025 | marketbeat.com

Metsera shares tumble as quarterly loss worse than expected

July 28, 2025 | uk.investing.com

Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress

July 28, 2025 | globenewswire.com

Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why

July 28, 2025 | zacks.com

Metsera (NASDAQ:MTSR) Shares Down 4.1% - Should You Sell?

July 24, 2025 | marketbeat.com

Metsera Inc.'s Lock-Up Period Will Expire on July 30th (NASDAQ:MTSR)

July 23, 2025 | marketbeat.com

Jennison Associates LLC Acquires New Position in Metsera Inc. (NASDAQ:MTSR)

July 21, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Makes New $13.11 Million Investment in Metsera Inc. (NASDAQ:MTSR)

July 20, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Stock Price Down 8.7% - What's Next?

July 18, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Hits New 1-Year High - Here's What Happened

July 18, 2025 | marketbeat.com

Metsera (MTSR) Presented at the 85th Scientific Sessions of the American Diabetes Association

July 14, 2025 | finance.yahoo.com

Alphabet Inc. Takes $135.06 Million Position in Metsera Inc. (NASDAQ:MTSR)

July 14, 2025 | marketbeat.com

Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

July 10, 2025 | zacks.com

Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why

July 10, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, IMVT, ACAD, and MTSR Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$25.15 -0.30 (-1.16%)

Closing price 03:59 PM Eastern

Extended Trading

$25.10 -0.05 (-0.21%)

As of 06:35 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Immunovant NASDAQ:IMVT

$15.89 +0.68 (+4.47%)

Closing price 04:00 PM Eastern

Extended Trading

$16.02 +0.13 (+0.79%)

As of 07:19 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

KalVista Pharmaceuticals NASDAQ:KALV

$12.59 +0.34 (+2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$12.70 +0.11 (+0.83%)

As of 07:56 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Metsera NASDAQ:MTSR

$30.87 -0.01 (-0.03%)

As of 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time